Meeting
2023 ASCO Gastrointestinal Cancers Symposium
CA125 kinetics as a potential biomarker for ascites progression during taxane plus ramucirumab therapy in patients with advanced gastric cancer.
Authors
Akira Ueda
Third Department of Internal Medicine, University of Toyama, Toyama, Japan;
Akira Ueda , Satoshi Yuki , Takayuki Ando , Iori Motoo , Ken Ito , Yosuke Kito , Miho Sakumura , Yuko Ueda , Shinya Kajiura , Naokatsu Nakada , Koji Nakajima , Ayumu Hosokawa , Kazuaki Harada , Yasuyuki Kawamoto , Yoshito Komatsu , Ichiro Yasuda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 437)
DOI
10.1200/JCO.2023.41.4_suppl.437
Abstract #
437
Poster Bd #
K3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
CA125 kinetics as a potential biomarker of prognosis in nivolumab monotherapy for patients with advanced gastric cancer and peritoneal metastasis.
First Author: Takayuki Ando
Poster
2013 Gastrointestinal Cancers Symposium
Early decline of CA125 to chemotherapy in advanced gastric cancer with peritoneal effusion.
First Author: Takayuki Ando
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
First Author: Toru Kadono
Poster
2022 ASCO Annual Meeting
VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.
First Author: Hiroo Katsuya